United States Uterine Fibroids Treatment Devices Market to Grow with a CAGR of 7.38% through 2030
Surge in research and development activities is
expected to drive the United States Uterine Fibroids Treatment Devices Market
growth in the forecast period, 2026-2030.
According to TechSci Research report, “United
States Uterine Fibroids Treatment Devices Market - By Region and Competition,
Forecast & Opportunities, 2030F”, the United States Uterine Fibroids
Treatment Devices Market stood at USD 512.35 Million in 2024 and is anticipated
to grow with a CAGR of 7.38% through 2030. Initiatives taken by government
based on uterine fibroids treatment devices has led to favorable market
conditions for the United States Uterine Fibroids Treatment Devices Market.
Several factors contribute to the growth of various uterine fibroids treatment devices
products.
One of the primary focuses of R&D efforts is the development
of minimally invasive and non-invasive treatment devices that offer faster
recovery times, reduced complications, and improved patient comfort compared to
traditional surgical procedures. Technologies such as magnetic resonance-guided
focused ultrasound (MRgFUS), radiofrequency ablation (RFA), and uterine artery
embolization (UAE) have benefited from ongoing research, leading to greater
precision, efficiency, and safety in treating uterine fibroids. These
advancements are shifting the market away from invasive procedures like
hysterectomy, encouraging wider adoption of innovative treatment options.
One of the most significant initiatives is federal research funding for uterine fibroids treatment. Agencies such as the National Institutes of Health (NIH) and the National Institute of Child Health and Human Development (NICHD) have allocated resources to study the causes, progression, and treatment options for uterine fibroids. The NIH funds research projects focused on minimally invasive and non-surgical treatment alternatives, leading to the development of advanced devices such as radiofrequency ablation (RFA) systems, uterine artery embolization (UAE) technologies, and magnetic resonance-guided focused ultrasound (MRgFUS).
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "United States Uterine Fibroids Treatment Devices Market”
The United States Uterine Fibroids Treatment Devices
Market is segmented into mode of treatment, technology, regional distribution,
and company.
Based on Mode of Treatment, Non-invasive
Treatment have emerged as the dominating segment in the United States Uterine
Fibroids Treatment Devices Market in 2024. Traditional surgical interventions,
such as hysterectomy and myomectomy, are associated with longer recovery times,
higher risks of complications, and potential fertility concerns. Non-invasive
treatments eliminate the need for incisions, reducing the risk of infection,
scarring, and post-surgical complications, making them the preferred choice for
patients and healthcare providers.
Based on Region, West have emerged as the fastest
growing region in the United States Uterine Fibroids Treatment Devices Market
in 2024. Patients in the West are increasingly opting for non-invasive
procedures such as MRI-guided focused ultrasound (MRgFUS) and uterine fibroid
embolization (UFE), which offer shorter recovery times and lower risks compared
to hysterectomy. Healthcare providers in states like California and Washington
are leading the adoption of robotic-assisted myomectomy and radiofrequency
ablation, driving market expansion.
Major companies operating in United States Uterine
Fibroids Treatment Devices Market are:
- Medtronic Plc
- Stryker Corporation
- Boston Scientific Corporation
- INSIGHTEC Ltd.
- CooperSurgical Inc.
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“Nanotechnology is revolutionizing targeted drug
delivery by enabling the development of nanoparticle-based therapies that
directly target fibroid tissue while minimizing systemic side effects.
Nanocarriers, such as liposomes and polymeric nanoparticles, are being utilized
to enhance the bioavailability of medications used in fibroid treatment, improve
localized drug release, reducing the impact on surrounding healthy tissues, and
minimize hormonal imbalances by optimizing the dosage of gonadotropin-releasing
hormone (GnRH) agonists and selective progesterone receptor modulators (SPRMs)”,
said Mr. Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“United States Uterine Fibroids Treatment
Devices Market By Mode of Treatment (Invasive Treatment, Minimally Invasive
Treatment, Non-invasive Treatment), By Technology (Surgical Techniques,
Laparoscopic Techniques, Ablation Techniques, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F”, has evaluated
the future growth potential of United States Uterine Fibroids Treatment Devices
Market and provides statistics & information on market size, structure, and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in United States Uterine
Fibroids Treatment Devices Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com